AI Biomarker Discovery Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 900.0 million
Estimated Base Value
2035 Forecast
US$ 2.4 billion
Projected Market Value
CAGR 2026–2035
10.3%
Compound Annual Growth
Largest Segment
AI Platforms & Software
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Europe
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Insilico Medicine
Emerging Players
Insitro, Xaira Therapeutics
AI Biomarker Discovery Market Overview
The AI Biomarker Discovery Market involves applying artificial intelligence, including machine learning and deep learning algorithms, to identify, validate, and develop novel biological markers. This market leverages extensive multi-omics and clinical datasets to accelerate drug discovery, predict therapeutic response, stratify patient populations, and improve diagnostic accuracy. It aims to enhance the efficiency and success rates of pharmaceutical R&D by uncovering new insights into disease mechanisms and treatment efficacy, thereby enabling more targeted and personalized medicine approaches. Key buyers include pharmaceutical companies, biotechnology companies, and contract research organizations.
The AI Biomarker Discovery Market is estimated at $900.0 Mn in 2025 and is forecast to reach $2.4 Bn in 2035, growing at a CAGR of 10.3% from 2025 to 2035. Demand is driven by the need for faster, more accurate drug discovery and development, the increasing complexity of biological data requiring advanced AI tools, and the high costs and low success rates of traditional biomarker research. However, high costs and long timelines for clinical validation, a lack of standardized, high-quality datasets for AI training, and navigating complex regulatory pathways present restraints.
The market is segmented by Type (AI Platforms & Software, AI-Powered Services, AI-Driven Drug Discovery Tools, AI-Assisted Diagnostics Development, AI-Based Predictive Modeling, Biomarker Data Analysis & Interpretation, Integrated AI Solutions, Others), Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Bioinformatics Algorithms, Predictive Analytics, Reinforcement Learning, Others), Application (Drug Discovery, Diagnostics Development, Personalized Medicine, Disease Prognosis & Monitoring, Therapeutic Target Identification, Clinical Trial Optimization, Companion Diagnostics, Toxicity Prediction), End-User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Diagnostic Laboratories, Healthcare Providers, Government & Regulatory Bodies, Others), Component (Software Platforms, Data Management & Analytics Tools, Consulting Services, Integration Services, Maintenance & Support Services, Algorithms & Models, Bioinformatics Databases, Others), and Stage (Early Discovery Phase, Preclinical Development, Clinical Trials Phase I, Clinical Trials Phase II, Clinical Trials Phase III, Companion Diagnostics Development, Post-Market Surveillance, Others). Regions served include Europe, North America, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, Tempus, Owkin, PathAI, Valo Health, ConcertAI, Deep Genomics, Freenome, and SOPHiA GENETICS. The full report covers market trends, drivers, restraints, and opportunities.
Market Definition & Overview
The AI Biomarker Discovery Market, situated within the Pharmaceutical and AI Bioinformatics industry, involves the application of artificial intelligence, including machine learning and deep learning algorithms, to identify, validate, and develop novel biological markers. This market leverages extensive multi-omics (genomic, proteomic, metabolomic, transcriptomic) and clinical datasets to accelerate drug discovery, predict therapeutic response, stratify patient populations, and improve diagnostic accuracy. It aims to enhance the efficiency, cost-effectiveness, and success rates of pharmaceutical R&D by uncovering new insights into disease mechanisms and treatment efficacy, thereby enabling more targeted and personalized medicine approaches.
Scope
- Global geographic coverage, with a focus on major R&D hubs.
- Pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic research institutions.
- Market analysis from 2025 to 2035.
Inclusions
- AI platforms and software specifically for biomarker identification and validation.
- Machine learning and deep learning algorithms applied to multi-omics data.
- Services for AI-driven target discovery and drug response prediction.
- Solutions for patient stratification and diagnostic biomarker development.
- Computational biology and bioinformatics tools utilizing AI for biomarker analysis.
- AI-powered analysis of genomic, proteomic, metabolomic, and clinical data for biomarker insights.
Exclusions
- Traditional, non-AI based biomarker discovery methods.
- General AI applications in pharmaceutical manufacturing or supply chain management.
- AI for clinical trial operations or patient recruitment platforms.
- AI-driven medical imaging analysis not specifically for biomarker identification.
- AI solutions developed for non-pharmaceutical or non-biomarker applications.
Market Size Forecast
Executive Summary
• The AI Biomarker Discovery market is valued at $900.0 Mn in 2025 and is forecast to reach $2.4 Bn by 2035, reflecting a robust CAGR of 10.3% as demand accelerates across every major segment and region over the ten-year outlook.
• AI Platforms & Software leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Europe commands the largest regional share at XX.X%, while Emerging Areas is expanding fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• The AI biomarker discovery market sees escalating M&A activity and strategic alliances, as larger pharmaceutical companies acquire innovative AI startups to integrate diverse data and advanced algorithmic capabilities across the value chain.
• Multi-omics data integration and sophisticated machine learning models are catalyzing rapid biomarker discovery, significantly shortening R&D cycles and propelling the industry towards highly personalized, data-driven therapeutic approaches.
• Evolving global regulatory clarity for AI-driven diagnostics is becoming paramount, fostering industry trust and accelerating market adoption by providing standardized pathways for biomarker validation and clinical implementation worldwide.
• The Asia-Pacific region is emerging as a pivotal growth frontier, fueled by extensive genomic data generation initiatives and increased investment, presenting significant opportunities for tailored AI biomarker solutions and partnerships.
• Robust venture capital infusion targets specialized AI biomarker platforms, necessitating superior data governance and secure cloud infrastructure to ensure scalable, ethical, and efficient discovery pipelines from research to clinic.
• Addressing data interoperability hurdles and ensuring rigorous algorithmic transparency are critical to unlocking the full potential and broader clinical translation of AI-discovered biomarkers into mainstream patient care.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The AI Biomarker Discovery Market was valued at $900.0 million in the base year, establishing its initial presence within the pharmaceutical and AI bioinformatics industries.
Future Market Projection
This market is projected for substantial growth, reaching $2.4 billion by the forecast year, indicating significant expansion and investment.
Robust Growth Outlook
The market demonstrates a robust Compound Annual Growth Rate (CAGR) of 10.3%, highlighting the accelerating adoption of AI in biomarker discovery.
Oncology Sector Dominance
The oncology segment is anticipated to be a leading driver within this market, propelled by the critical need for advanced diagnostic and therapeutic biomarkers.
Multi-Omics Integration
A notable trend is the increasing integration of multi-omics data using AI, enabling more comprehensive and accurate biomarker identification.
Precision Medicine Driver
The market underscores a pivotal shift towards precision medicine, leveraging AI for more targeted and personalized therapeutic strategies.
Market Dynamics
Market Trends
- Increased adoption of multi-omics data integration in AI models.
- Expansion of explainable AI (XAI) for biomarker identification.
- Growing use of real-world data (RWD) in discovery pipelines.
- Rise of federated learning for secure data sharing and analysis.
Growth Drivers
- Need for faster, more accurate drug discovery and development.
- Increasing complexity of biological data requires advanced AI tools.
- High costs and low success rates of traditional biomarker research.
- Rising prevalence of chronic diseases demanding targeted therapies.
Restraints
- High costs and long timelines for clinical validation impede adoption.
- Lack of standardized, high-quality datasets for AI training is a major hurdle.
- Navigating complex regulatory pathways for AI-driven biomarkers remains challenging.
- Integrating AI models into existing pharmaceutical R&D workflows is difficult.
Opportunities
- Personalized medicine and precision oncology applications are expanding.
- Developing AI solutions for rare disease biomarker identification.
- Partnerships between AI firms and pharmaceutical companies are crucial.
- Leveraging AI for companion diagnostics development offers new avenues.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI Platforms & SoftwareAI-Powered ServicesAI-Driven Drug Discovery ToolsAI-Assisted Diagnostics DevelopmentAI-Based Predictive ModelingBiomarker Data Analysis & InterpretationIntegrated AI SolutionsOthers |
| By Technology | Machine LearningDeep LearningNatural Language ProcessingComputer VisionBioinformatics AlgorithmsPredictive AnalyticsReinforcement LearningOthers |
| By Application | Drug DiscoveryDiagnostics DevelopmentPersonalized MedicineDisease Prognosis & MonitoringTherapeutic Target IdentificationClinical Trial OptimizationCompanion DiagnosticsToxicity Prediction |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesContract Research OrganizationsAcademic & Research InstitutesDiagnostic LaboratoriesHealthcare ProvidersGovernment & Regulatory BodiesOthers |
| By Component | Software PlatformsData Management & Analytics ToolsConsulting ServicesIntegration ServicesMaintenance & Support ServicesAlgorithms & ModelsBioinformatics DatabasesOthers |
| By Stage | Early Discovery PhasePreclinical DevelopmentClinical Trials Phase IClinical Trials Phase IIClinical Trials Phase IIICompanion Diagnostics DevelopmentPost-Market SurveillanceOthers |
Regional Analysis
- North America leads the AI biomarker discovery market, fueled by significant pharmaceutical R&D investment and a high concentration of biotech companies. Its robust technological infrastructure and substantial venture capital funding for AI in healthcare drive widespread adoption and innovation.
- Asia-Pacific emerges as the fastest-growing region, propelled by rising healthcare expenditure, a vast patient pool, and increasing chronic disease prevalence. Government initiatives promoting AI in healthcare and burgeoning local tech ecosystems are attracting significant investment and fostering rapid market expansion.
- Europe is notable for its emphasis on developing robust, ethical AI guidelines and fostering cross-border data sharing initiatives. This collaborative approach, combined with strong academic-industry partnerships, aims to accelerate AI biomarker discovery while addressing privacy concerns and ensuring responsible innovation.
| EuropeXX.X% | North AmericaXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- North America represents a developing share of this market, with growth shaped by regional demand and investment trends.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Latin America shows promising growth, albeit from a smaller base, as countries invest in improving healthcare infrastructure and embracing digital transformation.
- Strategic partnerships and increasing awareness of AI's potential in drug discovery are key drivers.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Europe is a major player driven by robust academic research, government initiatives supporting AI in healthcare, and a strong pharmaceutical sector.
- However, regulatory complexities and diverse national healthcare systems can sometimes moderate its growth pace compared to North America.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- The Asia Pacific region is experiencing rapid growth, fueled by increasing healthcare expenditure, a rising prevalence of chronic diseases, and substantial government support for AI and biotech in countries like China, India, and Japan.
- This region is becoming a hotbed for new research and development.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Characterized by nascent but rapidly developing markets, particularly in Gulf Cooperation Council (GCC) countries which are heavily investing in healthcare technology and diversification from oil.
- Government-led initiatives and foreign investments are crucial for market expansion.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | Leads globally in pharmaceutical R&D, AI innovation, and venture capital investment in biotech, driving significant advancements in AI-driven biomarker discovery for precision medicine. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | The largest economy in Latin America with a significant pharmaceutical market and growing digital health initiatives, making it a key player for AI adoption in drug discovery and diagnostics. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Europe's largest pharmaceutical market with a robust biotech sector and strong focus on precision medicine, leveraging AI for drug target identification and biomarker validation. |
| 4 | China | US$ XX.X Mn | XX.X% | Massive government and private investment in AI, genomics, and biopharmaceuticals drives rapid advancements in drug discovery and biomarker identification, aiming for global leadership. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Undergoing significant healthcare transformation with Vision 2030, driving substantial investment in biotech, digital health, and AI adoption for biomarker discovery and personalized medicine. |
Countries Covered (28)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Netherlands, Italy, Spain, Russia, Rest of Europe, China, Japan, South Korea, India, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Insilico Medicine | XX.X% | To accelerate drug discovery and development using a comprehensive AI-driven platform covering target identification to clinical trials. | — | — | Pharma.AIChemistry42Biology42+1 |
| 2 | BenevolentAI | XX.X% | To use AI and machine learning to identify novel drug targets, predict drug efficacy, and accelerate the drug discovery process. | — | — | Benevolent PlatformBenevolentAI Drug Discovery Pipeline |
| 3 | Recursion Pharmaceuticals | XX.X% | To industrialize drug discovery by integrating high-throughput wet-lab experimentation with advanced AI and machine learning on a massive scale. | — | — | Recursion OSRecursion Drug Discovery PipelinePhenom-MAP |
| 4 | Exscientia | XX.X% | To automate and accelerate drug discovery and development by combining AI with laboratory automation to identify and optimize novel drug candidates. | — | — | AI-driven Drug Discovery PlatformPrecision Drug DesignPipeline Assets |
| 5 | Tempus | XX.X% | To provide data-driven precision medicine solutions by leveraging AI to analyze vast amounts of clinical and molecular data for oncology and other diseases. | — | — | Tempus AI PlatformxTxG+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, Tempus, Owkin, PathAI, Valo Health, ConcertAI, Deep Genomics, Freenome, SOPHiA GENETICS, Nference, CytoReason, Cellarity, Relation Therapeutics, Healx, Envisagenics, Glympse Bio, Alchemab
The global AI Biomarker Discovery market features a competitive landscape led by Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, Tempus, and Owkin, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Insilico Medicine
BenevolentAI
Recursion Pharmaceuticals
Exscientia
Tempus
Owkin
PathAI
Valo Health
ConcertAI
Deep Genomics
Freenome
SOPHiA GENETICS
Nference
CytoReason
Cellarity
Relation Therapeutics
Healx
Envisagenics
Glympse Bio
Alchemab
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Pharma Giant 'GlobalBio' Partners with AI Leader 'Synapse AI' for Biomarker Discovery
GlobalBio Pharmaceuticals announced a strategic collaboration with Synapse AI, integrating Synapse's advanced AI platform to accelerate the identification of novel biomarkers across various therapeutic areas.
'BioSight AI' Unveils Next-Gen Platform for Multi-Omic Biomarker Identification
BioSight AI launched its groundbreaking 'OmicsPredict' platform, leveraging deep learning to analyze genomic, proteomic, and metabolomic data for more precise and rapid identification of disease biomarkers.
'Precision Diagnostics AI' Secures US$ XX.X in Series B Funding to Scale Biomarker R&D
Precision Diagnostics AI, a leader in AI-driven diagnostic biomarker discovery, successfully closed a US$ XX.X Series B funding round, fueling its expansion of research capabilities and clinical trial initiatives.
'MediCorp Pharma' Acquires 'Genomic Intelligence AI' to Bolster Precision Medicine Pipeline
MediCorp Pharma announced its acquisition of Genomic Intelligence AI, a specialized firm renowned for its AI algorithms in genomic biomarker discovery, enhancing MediCorp's precision medicine initiatives and drug development.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $900.0 Mn |
| Market Size (Forecast) | $2.4 Bn |
| CAGR | 10.3% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 28 Countries |
| Segments Covered | 6 Segments, 48 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the AI Biomarker Discovery Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The AI Biomarker Discovery market is estimated at $900.0 Mn in 2025. It is forecast to reach $2.4 Bn in 2035. These figures reflect the market's valuation and projected expansion over the next decade. The market's size indicates its growing importance in pharmaceutical R&D.
The AI Biomarker Discovery market is forecast to grow at a CAGR of 10.3% from 2025 to 2035. This growth rate reflects the increasing adoption of AI technologies in biomarker identification and validation. Factors like the need for faster drug discovery contribute to this expansion.
The main segments include Type (e.g., AI Platforms & Software), Technology (e.g., Machine Learning), Application (e.g., Drug Discovery), End-User (e.g., Pharmaceutical Companies), Component (e.g., Software Platforms), and Stage (e.g., Early Discovery Phase). These segments categorize the various aspects and applications within the market.
Leading companies in the AI Biomarker Discovery market include Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, Tempus, Owkin, PathAI, Valo Health, ConcertAI, Deep Genomics, Freenome, and SOPHiA GENETICS. These companies are key players in developing and providing AI solutions for biomarker discovery.
The AI Biomarker Discovery market report covers market trends, growth drivers, restraints, and opportunities. It provides a detailed analysis of market segmentation by various categories like Type, Technology, Application, End-User, Component, and Stage, across different geographic regions. It also profiles leading companies.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
AI Clinical Biomarker Discovery Market
$100.0 Mn in 2025 · 22.3% CAGR
AI Clinical Biomarker Platform Market
$700.0 Mn in 2025 · 22.0% CAGR
AI Drug Target Discovery Market
$250.0 Mn in 2025 · 19.6% CAGR
AI in Drug Discovery Market
$1.8 Bn in 2025 · 17.7% CAGR
Digital Biomarker Platform Market
$612.0 Mn in 2025 · 20.3% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR
AI Bioengineering Market
$2.7 Bn in 2025 · 25.5% CAGR
AI Bioinformatics Platform Market
$1.7 Bn in 2025 · 22.8% CAGR